Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report - Quiz - MDSpire

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • By

  • Fu-Yi Wang

  • Li-Long Zhu

  • Cheng Ji

  • Jie Deng

  • Lu Han

  • Fei Song

  • Zhong Chen

  • June 2, 2026

  • 0 min

Share

Original Source(s)

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

  • by Fu-Yi Wang, Li-Long Zhu, Cheng Ji, Jie Deng, Lu Han, Fei Song, Zhong Chen

  • June 2, 2026

Related Content

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms